Systemic Adjuvant Therapy with BCG Versus BCG + 5FU in Colorectal Cancer Dukes� Class C Updated Critical Analysis

The design of the best possible clinical trials of adjuvant interventions in colorectal cancer will entail the use of both time-tested and novel methods that allow efficient, reliable and patient-relevant therapeutic development. The ultimate goal of this endeavor is to safely and expeditiously bring to clinical practice novel interventions that impact patient lives. In this paper, we discuss statistical aspects and provide suggestions to optimize trial design, data collection, study implementation, and the use of predictive biomarkers and endpoints in phase 3 trials of systemic adjuvant therapy. We also discuss the issues of collaboration and patient centricity, expecting that several novel agents with activity in the (neo)adjuvant therapy of colon and rectal cancers will become available in the near future.

Download Full-text

Faculty Opinions recommendation of Older patients and adjuvant therapy for colorectal cancer: surgeon knowledge, opinions, and practice.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8877958.9671066 ◽

2011 ◽

Author(s):

Filippo La Torre

Keyword(s):

Colorectal Cancer ◽

Adjuvant Therapy ◽

Older Patients

Download Full-text

Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer

Nutrients ◽

10.3390/nu12020407 ◽

2020 ◽

Vol 12 (2) ◽

pp. 407

Author(s):

Reetta Holma ◽

Reijo Laatikainen ◽

Helena Orell ◽

Heikki Joensuu ◽

Katri Peuhkuri ◽

...

Keyword(s):

Colorectal Cancer ◽

Adjuvant Therapy ◽

Gastrointestinal Symptoms ◽

Mucosal Injury ◽

Dietary Carbohydrates ◽

Food Diary ◽

High Consumption ◽

Increased Risk ◽

Symptom Diary ◽

Low Consumption

Chemotherapy-induced mucosal injury of the small intestine may interfere with the enzymes and transporters responsible for the hydrolysis and absorption of dietary carbohydrates causing diarrhoea, abdominal discomfort and pain. The aim of this study was to investigate the association between the consumption of foods rich in FODMAPs (fermentable oligo-, di- and monosaccharides and polyols) and gastrointestinal symptoms in patients receiving adjuvant therapy for colorectal cancer. The patients (n = 52) filled in a 4-day food diary at baseline and during therapy and kept a symptom diary. The intakes of FODMAP-rich foods were calculated as portions and the intakes were divided into two consumption categories. Patients with high consumption of FODMAP-rich foods had diarrhoea more frequently than those with low consumption (for lactose-rich foods the odds ratio (OR) was 2.63, P = 0.03; and for other FODMAP-rich foods 1.82, P = 0.20). Patients with high consumption of both lactose-rich and other FODMAP-rich foods had an over 4-fold risk of developing diarrhoea as compared to those with low consumption of both (OR, 4.18; P = 0.02). These results were confirmed in multivariate models. Conclusion: Consumption of lactose-rich foods results in an increased risk of diarrhoea during adjuvant therapy for colorectal cancer, especially when the consumption of other FODMAP-rich foods is also high.

Download Full-text